Co-developed accredited symposium
Friday, June 16, 2017, 0630–0800
Breakfast to be served from 0600
Palais des congrès, Room 519AB
Join our distinguished faculty for an exciting symposium on our ever-evolving understanding of the pathophysiology of ocular surface disease. Our Canadian speakers will share their expertise and clinical cases to help you improve your practical management of this complex disease. Topics will include the causes of dry eye, diagnosis, “point-of-care testing,” as well as current and upcoming therapeutic options and their mechanisms of action. Understanding the challenging patient with keratoneuralgia (“Pain Without Stain”), enhancing outcomes of cataract surgical cases and managing ocular surface disease associated with glaucoma and meibomian gland disease will be highlighted. The interactive case-based symposium format will ensure attendees have ample time for questions.
Learning objectives
At the end of this symposium, participants will be able to:
- Discuss the pathophysiology, diagnosis and current therapies for patients with ocular surface disease, including those being evaluated for ocular surgery or on glaucoma therapy.
- Describe the most significant advances in our understanding of ocular surface disease.
- Recognize and treat the most common causes of dry eye: Meibomian gland dysfunction and other lid diseases.
- Identify how to manage dry eyes before and after cataract surgery.
- Describe keratoneuralgia and its various treatment strategies.
Scientific Planning CommitteeW. Bruce Jackson, MD Chair |
FacultyJohanna Choremis, MD |
0630 | Welcome and introductions • W. Bruce Jackson, MD |
0635 | Ocular surface disease in 2017: Have we made progress? • W. Bruce Jackson, MD |
0645 | MGD and blepharitis: Get those creepers off my peepers! • Setareh Ziai, MD |
0700 | Surface matters in cataract surgery • Louis Racine, MD |
0715 | Pain without stain • Johanna Choremis, MD |
0730 | Glaucoma and dry eye: Pressure, preservatives and protecting the surface • Walter Delpero, MD |
0745 | Panel discussion and Q&A |